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Colleagues and friends—welcome to the 57th Annual
Meeting of the American Society of Human Genetics. I
thank you for the honor of serving as your president. We
come together with good reason to celebrate: There has
never been a better time for human genetics research.
Genomic tools are providing us with new insights about
genomic structure and gene function; the pace of gene dis-
covery is faster than ever; and we now have a handful of
innovative therapies based on genetic research, with
prospects of more to come. This success derives in part
from the wide range of research strategies that have been
brought to bear on questions related to human genetics.
It also reﬂects the dedication of our members. The success
brings new—and welcome—challenges.
The fundamental goal of human genetics research is to
develop new knowledge that will provide beneﬁt to indi-
viduals, families, and society. In addition to excellence in
research, our Society’s vision statement calls for the trans-
lation of ‘‘new ideas into improved clinical practice.’’1 AnThe Amanalysis by Gregory Treverton, from the ﬁeld of strategic
defense, provides a useful way of thinking about the
challenges involved in this undertaking: Questions, he
argues, should be characterized as either puzzles or myster-
ies.2 The distinction offers an interesting perspective for
human genetics.
A puzzle is a question that can be answered, given
enough data. Where, for example, is Osama bin Laden? A
puzzle has ‘‘already happened . the result has occurred,
though it may not yet be known.’’2 From this perspective,
puzzles are the central concern of science. And scientists
have had extraordinary success in developing knowledge
about the structure of the environment, the physiology
of living organisms, and the complex interaction between
the two.
Over more than a century, researchers in human genet-
ics have contributed importantly to this effort, taking on
complex puzzles such as the laws of inheritance, the chem-
ical composition of genes, and the biochemical basis of
disease. One of the most recent and grandest successes,
the Human Genome Project (HGP),3 illustrates the itera-
tive nature of scientiﬁc puzzle solving. The HGP could be
envisioned only after the seminal discoveries of the mid-
20th century: the DNA helix, the genetic code, recombi-
nant DNA technology, and growing knowledge about the
genomic structure of simple organisms.4 Successful com-
pletion of the HGP required the solution of many smaller
puzzles, including developments in technology that
allowed for highly efﬁcient sequencing.
A mystery, by contrast, is a question that cannot be
answered with certainty.2 Will North Korea keep its part
of the nuclear bargain? Will democracy take hold in the
former Soviet nations? Mysteries may reveal themselves
over time and often have a preferred outcome. However,
there is not, even in principle, a ‘‘right’’ answer because
mysteries are based on complex situations for which the
outcome is contingent, depending on the future interac-
tion of many known and unknown factors.2 The task in
addressing mysteries is to identify and analyze the contrib-
uting factors, using expertise and judgment to identify
actions that promote the best chances of a good outcome;
in some cases, part of the mystery is to deﬁne what consti-
tutes a good outcome.
The way forward in human genetics involves taking on
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of scientiﬁc puzzles, we are able to tackle the next; at this
meeting, for example, we see progress ﬂowing from the
use of genomic tools to identify genes, characterize their
function, and lay the groundwork for a detailed molecular
understanding of biological systems. However, providing
beneﬁt from this growing knowledge—and avoiding
harm—takes us into the realm of mysteries.
For example, genome-wide association studies are
achieving remarkable success in identifying gene variants
associated with the common multifactorial diseases that
account for the majority of the public health burden.
These discoveries offer great promise through the identiﬁ-
cation of biological functions and pathways associated
with disease, extending the beneﬁt that genetic research
is already providing for single-gene diseases.5 Gene-disease
associations can also be used to identify individuals at in-
creased risk. Unlike the genotypes that account for classic
genetic diseases, however, most gene variants associated
with common multifactorial diseases have only a modest
effect on phenotype. Their signiﬁcance can readily be over-
estimated, particularly by media prone to exaggerating the
causal role of genetics.6
Some of the complexities involved in determining the
appropriate use of genetic susceptibility tests are illustrated
by the genetics of age-relatedmacular degeneration (AMD).
As part of the recentwave of genome-wide association stud-
ies, several gene variants associated with either increased or
decreased risk of AMDhave been identiﬁed.7,8 Although in-
dividual gene variants have limited ability to predict indi-
vidual risk, combinations of variants can identify a small
proportion of individuals with very high or very low risk.8
Under what circumstances does a test of this kind provide
clinical value? The answer to this question depends on
many interacting factors, some of which are not yet de-
ﬁned, including the cost of testing, the safety, efﬁcacy and
cost of therapeutic options available to reduce risk or treat
early disease, and the potential for discrimination, stigma,
or exposure to unnecessary healthcare based on knowledge
of genetic risk.
AMD is an early example of the opportunities and ques-
tions arising with growing knowledge of human genetics.
Answers to the question of clinical utility will vary with
differences in the predictive value of the test, disease sever-
ity, treatment options, and healthcare context. Uncer-
tainties about risk and beneﬁt are even greater for tests
based on genetic associations with behavioral traits. These
new testing opportunities will undoubtedly provide
important healthcare beneﬁts in some clinical settings;
they are also likely to provide limited beneﬁt or the poten-
tial for net harm in others.9 The challenge is to deﬁne and
consider the parameters that contribute to risk and beneﬁt
and to develop deliberative procedures to chart a responsi-
ble course forward. The questions involved are inherently
transdisciplinary, requiring the sharing of expertise from
ﬁelds as diverse as economics, law, ethics, psychology, ed-
ucation, medical anthropology, and sociology.10 As with
other mysteries, addressing these testing opportunities1030 The American Journal of Human Genetics 82, 1029–1031, Maywill require both data and judgment; policy analysis, ethi-
cal guidance and educational initiatives are all needed, in-
formed by robust data on clinical, social, and economic
outcomes.
This expanding research agenda comes at a time when
review of genetic research is increasingly challenging for
Institutional Review Boards (IRBs). The combination of
genomic technologies, the creation of large biobanks,
and plans for rapid data sharing pose new questions for
IRBs. Experts are debating the preferred approaches to pri-
vacy protection, family-based recruitment, data sharing,
return of results, and avoidance of group harm,11–15 at
a time when there is already evidence of considerable var-
iation among IRBs in the interpretation of risks and bene-
ﬁts related to genetic research.16 Two examples serve to
illustrate the difﬁculty of the problems to be solved.
Exploratory research in human genetics is typically done
with the understanding that individual research results
will not be returned to participants. This approach is ethi-
cally sound when the data produced by the study are pre-
liminary or not yet validated. But when data generated
have clear clinical signiﬁcance—as, for example, when a
genomic study reveals a mutation associated with Lynch
syndrome, thus identifying the participant as someone
who would beneﬁt from early and frequent colon cancer
screening—researchers arguably have a moral obligation
to disclose results.13 When genomic research is based on
shared data from large repositories, fulﬁlling such obliga-
tions is logistically difﬁcult and may be possible only
with planning and dedicated resources. For reasons of
participant protection as well as research efﬁciency, careful
thought needs to be given to the data characteristics that
might mandate the return of results. This question paral-
lels the clinical utility issues raised by genetic susceptibil-
ity testing: What genetic-risk information matters? And
should the threshold be higher for research disclosure than
for clinical use? A broad consensus is needed, taking into ac-
count both the well-being of research participants and the
requirements and beneﬁcial potential of good science.
The issue of group harm is another area requiring delib-
eration. Recent events—such as the use of data collected
from members of the Havasupai tribe for purposes not au-
thorized by the tribe,17 and the claim (now refuted) that
a gene variant putatively associated with brain develop-
ment was selected for in European and Asian but not
in African populations18—generate legitimate concerns
about how genetic research will be conducted and inter-
preted. Our Society’s mission includes promoting ‘‘respon-
sible social and scientiﬁc policies’’1, and our code of ethics
calls for a commitment to building public trust through
accountability.19 We have an obligation to ensure that all
groups in our society beneﬁt from human genetics re-
search. As a corollary, we need to help craft research strat-
egies that provide appropriate protection to groups as well
as individuals,14 guard against discriminatory and defama-
tory uses of genetic data, and speak out when science is
misinterpreted or misused.202008
Our Society can take a leadership role in resolving new
and challenging questions related to responsible human
genetics research and practice, along with partners in our
sister genetics societies. An important component of this
effort is to overcome communication barriers, ensuring
effective dialogue among basic and clinical researchers,
clinicians, community partners, and the host of disciplines
involved in addressing social and policy issues. Our success
in attracting an expanding number of disciplines under
the Society’s umbrella is a promising sign. About 7% of
our members list ethics, social, legal, and policy issues as
their primary interest area, 4% list public health genetics,
and 2% list DNA forensics. These statistics point to the
growing societal importance of human genetics. Another
indicator is our Society’s support of policy initiatives,
including policy statements on topics such as direct-to-
consumer testing,21 support of legislation such as laws
banning genetic discrimination, and joint efforts with
the National Human Genome Research Institute and the
Centers for Disease Control and Prevention to create
policy-oriented fellowships.
Moving forward, we need to forge collaborative partner-
ships to promote the wise use of genetic knowledge. As
part of this effort, we need to be sure our umbrella is big
enough to make room for everyone who shares our vi-
sion. For the past two years, our Society has extended
a special welcome to advocates for families living with ge-
netic disease. Our educational programs have sought to
reach out to students from diverse backgrounds and to
provide assistance to teachers working in poorly resourced
classrooms. Are we doing enough? Science will always be
at the core of our mission, but ensuring the beneﬁts of sci-
ence requires that we acknowledge the mysteries arising
from our work and the many partnerships that will allow
us to address them. We need to create a common language
that enables us to share expertise across a broad range
of experiences and perspectives, promote science educa-
tion, work in partnership with advocates and research
participants, and expand the scope of our research to en-
sure meaningful assessment of societal beneﬁt. These
challenges represent a new wave of opportunity for our
Society.
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